← Leaderboards
Julie A Sterling
Vanderbilt University
$3,669,071
Attributed
$8,131,690
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,131,690 · 5
VA$0 · 3
By mechanism
T32$4,536,754 · 2
R01$3,453,236 · 2
F32$141,700 · 1
I01$0 · 2
IK6$0 · 1
Top collaborators
- C. Henrique Serezani6 shared
- Digna R Velez Edwards6 shared
- Scott A Guelcher5 shared
- Craig Lewis Duvall3 shared
- Justin M Balko1 shared
- Alissa M Weaver1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Harold L Moses$33,288,478
- Ann Richmond$15,857,391
- Sebastian Joyce$13,492,547
- Raymond Nelson Dubois$22,706,669
- Laurence J Zwiebel$9,792,749
Others in their field
Top investigators on “Tumor Growth”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,387,105
- Israel David Goldman · Yeshiva University$49,502,983
- Candace S Johnson · University Of Pittsburgh At Pittsburgh$44,839,363
- C Kent Osborne · Baylor College Of Medicine$40,237,256
- Alan F Horwitz · University Of Virginia Charlottesville$39,846,480
- Douglas Yee · University Of Minnesota$38,475,268
Research focus
Tumor GrowthTumorNeoplastic CellBone DiseasesSiteNeoplasm MetastasisBoneMouse ModelTranscription FactorTumor BurdenMetastatic Neoplasm To The BoneParathyroid Hormone-Related ProteinFractureMalignant Breast NeoplasmCellsBone MarrowMalignant NeoplasmsProstateResponsePre-Clinical ModelSignal TransductionRegulationImmuneLead
Grant awards (35)
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$648,024
R01 · FY2025 · CA · contact PI
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$523,872
T32 · FY2025 · GM
Microenvironmental Influences in Cancer$442,933
T32 · FY2025 · CA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2025 · VA · contact PI
Reprogramming tumor associated macrophages to induce anti-tumor immune responses in bone metastatic breast cancer.$0
I01 · FY2025 · VA · contact PI
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$804,635
T32 · FY2024 · GM
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$616,177
R01 · FY2024 · CA · contact PI
Reprogramming tumor associated macrophages to induce anti-tumor immune responses in bone metastatic breast cancer.$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$804,388
T32 · FY2023 · GM
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$667,924
R01 · FY2023 · CA · contact PI
Microenvironmental Influences in Cancer$432,752
T32 · FY2023 · CA · contact PI
Reprogramming tumor associated macrophages to induce anti-tumor immune responses in bone metastatic breast cancer.$0
I01 · FY2023 · VA · contact PI
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$769,330
T32 · FY2022 · GM
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$32,316
T32 · FY2022 · GM
Reprogramming tumor associated macrophages to induce anti-tumor immune responses in bone metastatic breast cancer.$0
I01 · FY2022 · VA · contact PI
Initiative for Maximizing Student Development (IMSD) at Vanderbilt$726,528
T32 · FY2021 · GM
Targeting the Bone Microenvironment to Reduce Tumor-induced Bone Disease$0
I01 · FY2020 · VA · contact PI
Targeting the Bone Microenvironment to Reduce Tumor-induced Bone Disease$0
I01 · FY2019 · VA · contact PI
Targeting the Bone Microenvironment to Reduce Tumor-induced Bone Disease$0
I01 · FY2018 · VA · contact PI
Targeting the Bone Microenvironment to Reduce Tumor-induced Bone Disease$0
I01 · FY2017 · VA · contact PI
The Role of Mechanotransduction in Progression of Tumor-induced Bone Disease$315,650
R01 · FY2016 · CA
Strategies for early treatment of bone metastases$0
I01 · FY2016 · VA · contact PI
The Role of Mechanotransduction in Progression of Tumor-induced Bone Disease$309,945
R01 · FY2015 · CA
Strategies for early treatment of bone metastases$0
I01 · FY2015 · VA · contact PI
The Role of Mechanotransduction in Progression of Tumor-induced Bone Disease$302,315
R01 · FY2014 · CA
Strategies for early treatment of bone metastases$0
I01 · FY2014 · VA · contact PI
The Role of Mechanotransduction in Progression of Tumor-induced Bone Disease$285,659
R01 · FY2013 · CA
Strategies for early treatment of bone metastases$0
I01 · FY2013 · VA · contact PI
The Role of Mechanotransduction in Progression of Tumor-induced Bone Disease$307,542
R01 · FY2012 · CA
Regulation of PTHrP expression in chondrocytes by Gli2$50,428
F32 · FY2006 · AR · contact PI
Regulation of PTHrP expression in chondrocytes by Gli2$38,400
F32 · FY2005 · AR
Regulation of PTHrP expression in chondrocytes by Gli2$9,896
F32 · FY2005 · AR
Regulation of PTHrP expression in chondrocytes by Gli2$42,976
F32 · FY2004 · AR